Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, launched a Patient Impact Grant Program offering three $20,000 grants to non-profit, mission-driven organizations. Funding targets community support, education and stigma reduction, and ecosystem innovation and independent research in mental health.
A review panel including AtaiBeckley leaders and an external expert from Mental Health America will select recipients. Applications are open now and close on September 1.
AtaiBeckley (NASDAQ: ATAI) will participate in several investor conferences in June 2026, including events hosted by Jefferies, Oppenheimer, HCW and UBS, featuring fireside chats, presentations and one-on-one meetings.
Live and archived webcasts will be accessible via AtaiBeckley’s investor relations website.
AtaiBeckley (NASDAQ: ATAI) reported Q1 2026 results and a pipeline update. Cash, cash equivalents and short-term securities were $209.9 million, expected to fund operations into 2029, including anticipated BPL-003 Phase 3 topline readouts.
BPL-003 for treatment-resistant depression is on track to start a two‑study Phase 3 program in Q2 2026. VLS-01 Phase 2 topline results are anticipated in Q4 2026, and EMP-01 Phase 2a data showed improvements across multiple social anxiety measures. R&D and G&A increased, driving a $29.8 million net loss.
AtaiBeckley (NASDAQ: ATAI) received the Silver Award in OVID Health’s 2026 Patient Participant Index for its multiyear collaboration with PsyPAN to integrate participant insights into psychedelic clinical research.
Highlights include 2023 co‑designed qualitative workshops, the white paper “The Participants in Their Own Words,” a 12‑month unrestricted grant enabling a 2025 peer‑support pilot, and expanded academic and international advocacy partnerships.
AtaiBeckley (NASDAQ: ATAI) reported peer‑reviewed Phase 2a results showing a single intranasal dose of BPL‑003 produced a 66.7% antidepressant response rate by Day 2 in SSRI‑concomitant TRD patients (n=12) and durable responses at Day 85: 83% (10 mg) and 66.7% (12 mg).
FDA Breakthrough Therapy designation granted Oct 2025; Phase 3 initiation is on track for Q2 2026 following FDA End‑of‑Phase 2 alignment.
AtaiBeckley (NASDAQ: ATAI) was added to the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indices, effective March 23, 2026. Inclusion in CRSP triggers mandatory position-building by passive index funds tracking more than $3 trillion in assets.
The company said its BPL-003 Phase 3 program remains on track to initiate in Q2 2026, with topline VLS-01 Phase 2b data expected in H2 2026. These additions follow inclusion in the Nasdaq Biotechnology Index in December 2025.
AtaiBeckley (NASDAQ: ATAI) reported peer-reviewed Phase 2a Cohort 1 results for BPL-003 in treatment-resistant depression (TRD). A single 10 mg intranasal dose produced a mean MADRS reduction of 12.6 points by Day 2 (27.5 to 14.8), sustained to Day 85 (14.5).
Response rate ≥50% was 54.5% through Day 85; 63.6% achieved remission at one or more timepoints. SHAPS improved from 8.4 to 1.5. No serious adverse events or withdrawals were reported. Phase 3 remains on track to initiate in Q2 2026 after a successful EOP2 meeting.
AtaiBeckley (NASDAQ: ATAI) said it remains on track to start two parallel Phase 3 studies of BPL-003 in Q2 2026 after a successful End-of-Phase 2 meeting with the FDA. BPL-003 holds Breakthrough Therapy Designation and showed rapid Day 2 antidepressant effects and durable improvements through eight weeks in Phase 2b.
The company reaffirmed cash runway into early 2029, outlined a scalable commercial model aligned with interventional psychiatry workflows, noted positive Phase 2a results for EMP-01, and expects VLS-01 Phase 2 topline in H2 2026.
AtaiBeckley (NASDAQ: ATAI) reported Q4 and full-year 2025 results and clinical updates on March 6, 2026. Key clinical milestones include a successful FDA End-of-Phase 2 meeting for BPL-003 and Phase 3 initiation targeted for Q2 2026, VLS-01 Phase 2 topline readout expected in H2 2026, and positive Phase 2a EMP-01 SAD results. Financially, cash and short-term securities totaled $220.7M at year-end and management expects runway into early 2029. The company completed a strategic combination and U.S. redomiciliation in late 2025.
AtaiBeckley (NASDAQ: ATAI) announced a successful End-of-Phase 2 meeting with the FDA for BPL-003, its intranasal mebufotenin benzoate for treatment-resistant depression. The FDA indicated support for a dual pivotal Phase 3 program and provided feedback on the safety database.
The company expects Phase 3 initiation on track for Q2 2026, notes BPL-003 has Breakthrough Therapy designation (Oct 2025), and will host a Virtual Investor Day on March 6, 2026 to detail the Phase 3 strategy.